131 related articles for article (PubMed ID: 29479886)
21. [Correlation of the levels of the bone turnover markers BAP and β-CTX with bone metastasis progress in lung cancer patients].
Tang Q; Zhao H; Jia R; Liu L
Zhongguo Fei Ai Za Zhi; 2013 Mar; 16(3):144-7. PubMed ID: 23514943
[TBL] [Abstract][Full Text] [Related]
22. Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma.
Yoshida K; Sumi S; Arai K; Koga F; Umeda H; Hosoya Y; Honda M; Yano M; Moriguchi H; Kitahara S
Cancer; 1997 Nov; 80(9):1760-7. PubMed ID: 9351545
[TBL] [Abstract][Full Text] [Related]
23. Procollagen I carboxyterminal propeptide (PICP) as a bone formation marker and carboxyterminal telopeptide of type I collagen (ICTP) as a bone degradation marker in children with chronic renal failure under conservative therapy.
Polak-Jonkisz D; Zwolińska D; Bednorz R; Owczarek H; Szymańska A; Nahaczewska W
Med Sci Monit; 2003 Jan; 9(1):CR19-23. PubMed ID: 12552245
[TBL] [Abstract][Full Text] [Related]
24. Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy.
Lumachi F; Basso SM; Camozzi V; Tozzoli R; Spaziante R; Ermani M
Clin Chim Acta; 2016 Sep; 460():227-30. PubMed ID: 27404457
[TBL] [Abstract][Full Text] [Related]
25. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD
Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
[TBL] [Abstract][Full Text] [Related]
26. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
Berruti A; Piovesan A; Torta M; Raucci CA; Gorzegno G; Paccotti P; Dogliotti L; Angeli A
Br J Cancer; 1996 Jun; 73(12):1581-7. PubMed ID: 8664134
[TBL] [Abstract][Full Text] [Related]
27. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP.
Jukkola A; Tähtelä R; Thölix E; Vuorinen K; Blanco G; Risteli L; Risteli J
Cancer Res; 1997 Dec; 57(24):5517-20. PubMed ID: 9407961
[TBL] [Abstract][Full Text] [Related]
28. [Clinical characteristics of bone disease in multiple myeloma and clinical significance of monitoring bone metabolic markers].
Chu B; Lu MQ; Wu MQ; Shi L; Fu LN; Gao S; Fang LJ; Xiang QQ; Bao L
Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1424-9. PubMed ID: 27266350
[TBL] [Abstract][Full Text] [Related]
29. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen as markers of bone metastases in patients with prostate carcinoma.
Hosoya Y; Arai K; Honda M; Sumi S; Yoshida K
Eur Urol; 1997; 31(2):220-3. PubMed ID: 9076470
[TBL] [Abstract][Full Text] [Related]
31. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
Katagiri M; Fukunaga M; Ohtawa T; Harada T
World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
[TBL] [Abstract][Full Text] [Related]
32. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis.
Lammi L; Kinnula V; Lähde S; Risteli J; Pääkkö P; Lakari E; Ryhänen L
Eur Respir J; 1997 Dec; 10(12):2725-30. PubMed ID: 9493651
[TBL] [Abstract][Full Text] [Related]
33. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
[TBL] [Abstract][Full Text] [Related]
34. Age related changes in biochemical markers of bone metabolism in horses.
Price JS; Jackson B; Eastell R; Goodship AE; Blumsohn A; Wright I; Stoneham S; Lanyon LE; Russell RG
Equine Vet J; 1995 May; 27(3):201-7. PubMed ID: 7556047
[TBL] [Abstract][Full Text] [Related]
35. Comparison of assay of total and bone-specific alkaline phosphatase in the assessment of osteoblast activity in patients with metastatic bone disease.
Piovesan A; Berruti A; Torta M; Cannone R; Sperone P; Panero A; Gorzegno G; Termine A; Dogliotti L; Angeli A
Calcif Tissue Int; 1997 Nov; 61(5):362-9. PubMed ID: 9351876
[TBL] [Abstract][Full Text] [Related]
36. Bone remodeling markers in the detection of bone metastases in prostate cancer.
de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J
Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863
[TBL] [Abstract][Full Text] [Related]
37. New and traditional serum markers of bone metabolism in the detection of skeletal metastases.
Plebani M; Bernardi D; Zaninotto M; De Paoli M; Secchiero S; Sciacovelli L
Clin Biochem; 1996 Feb; 29(1):67-72. PubMed ID: 8929827
[TBL] [Abstract][Full Text] [Related]
38. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
[TBL] [Abstract][Full Text] [Related]
39. Collagen derived serum markers in carcinoma of the prostate.
Rudnicki M; Jensen LT; Iversen P
Scand J Urol Nephrol; 1995 Sep; 29(3):317-21. PubMed ID: 8578275
[TBL] [Abstract][Full Text] [Related]
40. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
